IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients

Table 1 Demographic and clinical features of 118 hepatitis C virus genotype 1 infected patients n (%)

Variables	Patients
Age, yr	49 (16)
Male gender	52.5%
BMI, kg/m2	23.5 (3.6)
AST, IU/mL	82 (71)
ALT, IU/mL	55 (48)
gGT, IU/mL	46 (57)
Platelets, 109 L	182 (90)
APRI index	0.4 (0.6)
Basal HCV RNA, log IU/mL	6 (1.1)
Fibrosis (stiffness)	6.7 (19)
Fibrosis Metavir
F0-F1-F2	20 (25)
F3-F4	59 (75)
IL28B SNP rs8099917
TT	59 (50)
TG	56 (47)
GG	3 (3)
IL28B SNP rs12979860
CC	30 (25)
CT	73 (62)
TT	15 (13)
HCV RNA decline < 1 log10 IU/mL w4	26 (22)
rs8099917_G*/rs12979860_**	21 (81)
rs8099917_TT/rs12979860_T*	3 (11)
rs8099917_TT/rs12979860_CC	2 (8)
Therapy outcome
R	53 (55)
NR	65 (45)

Data are reported as median (interquartile range) and frequencies (%). IL: Interleukin; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; gGT: Gamma-glutamyl transpeptidase; IL28B: Interleukin-28B; SNP: Single nucleotide polymorphism; w4: Treatment week 4; R: Responder; NR: Non-responder.